Early pregnancy : biology and medicine : the official journal of the Society for the Investigation of Early Pregnancy最新文献

{"title":"Localization of fos, jun, kit and SCF mRNA in human placenta throughout gestation using in situ RT-PCR.","authors":"L Doneda,&nbsp;G Bulfamante,&nbsp;M G Grimoldi,&nbsp;L Volpi,&nbsp;L Larizza","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The expression pattern of c-fos, c-jun, c-kit and stem cell factor (SCF) has been investigated in developing human placenta using the highly sensitive technique of in situ reverse transcriptase-polymerase chain reaction (RT-PCR). Specific transcripts of all genes under study were observed in first-trimester placenta sections. c-fos, c-jun, c-kit and SCF transcripts were localized in cells of the villous stroma; fos, jun and kit-specific mRNAs were also found in endothelial cells; fos, kit and SCF mRNAs were detected in villous trophoblast cells. In mid-trimester and term placenta specimens only SCF transcripts were observed, restricted to trophoblast cells. The lack of c-fos transcripts in placenta from the second and third trimesters is a finding that contrasts with data from the literature obtained using extractive techniques. Parallel immunocytochemistry of placenta specimens from the three pregnancy stages under study revealed the fos protein only in first-trimester placenta, in agreement with the in situ RT-PCR findings. We conclude that the in situ RT-PCR technique is most suitable for gene expression studies because of its high level of sensitivity in correctly assigning the signal to specific cell types in complex tissues.</p>","PeriodicalId":11444,"journal":{"name":"Early pregnancy : biology and medicine : the official journal of the Society for the Investigation of Early Pregnancy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1997-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20958601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between trophoblast differentiation and the production of bioactive hCG.","authors":"H H Ho,&nbsp;G C Douglas,&nbsp;Q F Qiu,&nbsp;T L Thirkill,&nbsp;J W Overstreet,&nbsp;B L Lasley","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We previously showed that a significant number of failing pregnancies are associated with production of human chorionic gonadotropin (hCG) having relatively low bioactivity. The present study was designed to compare the secretion of intact, immunoreactive hCG to the secretion of bioactive hCG during trophoblast differentiation, and to test the hypothesis that the lower bioactive: immunoreactive hCG ratios in failing pregnancies are related to reduced or impaired trophoblast differentiation. Cytotrophoblast cells were isolated from term placentas and cultured under conditions that induced or did not induce syncytiotrophoblast formation. Culture media were collected at regular intervals up to 72 h and levels of immunoreactive and bioactive hCG were measured. The differentiation of cytotrophoblast cells to multinucleated syncytiotrophoblast was monitored by immunocytochemistry and electron microscopy. During the 72 h culture period, concentrations of immunoreactive and bioactive hCG increased in both differentiating and non-differentiating cells. However, the concentrations of immunoreactive and bioactive hCG were higher under culture conditions that promoted trophoblast differentiation. Furthermore, the ratio of bioactive hCG to immunoreactive hCG was higher in differentiating cultures. When differentiation was inhibited by dimethyl sulfoxide, the secretion of bioactive hCG was reduced and the bioactive: immunoreactive hCG ratio did not change. These findings are consistent with the idea that production of bioactive hCG accompanies syncytiotrophoblast formation.</p>","PeriodicalId":11444,"journal":{"name":"Early pregnancy : biology and medicine : the official journal of the Society for the Investigation of Early Pregnancy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1997-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20958604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A re-examination of the association of 'early pregnancy factor' activity with fractions of heterogeneous molecular weight distribution in pregnancy sera.","authors":"G Di Trapani,&nbsp;C Orozco,&nbsp;I Cock,&nbsp;F Clarke","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The association of 'early pregnancy factor' ('EPF') activity in early pregnancy sera with multiple fractions of heterogeneous molecular mass was re-examined to test whether previously perplexing observations could be explained by a new multi-factorial model of the serum components required for this activity expression. Gel permeation fractionation of human pregnancy sera revealed 'EPF' activity associated with fractions containing components ranging in MW from < or = 1 kDa to > or = 500 kDa. A significant activity peak was observed eluting on the total volume (Vt) of the column, indicating the presence of active molecules of very low molecular mass. Multiple activity peaks were also observed in the macromolecular fractionation region ranging in apparent molecular weight from 12 kDa, through 25, 70 and 250 to > or = 500 kDa. Analysis of these fractions revealed that they all contained thioredoxin and active moieties of low molecular mass, with the latter probably directly associated with the former. Adsorption with specific anti-thioredoxin antibodies removed from these fractions the capacity to display 'EPF' activity. Further analyses revealed that in these fractions thioredoxin played a permissive role allowing the low molecular mass active moieties to express activity in the bioassay in the presence of otherwise counteracting substances. The results of these studies are consistent with the proposal that 'EPF' activity expression in pregnancy sera is due to the presence of a multi-factorial system in which thioredoxin plays an essential permissive role in concert with active moieties of low molecular mass.</p>","PeriodicalId":11444,"journal":{"name":"Early pregnancy : biology and medicine : the official journal of the Society for the Investigation of Early Pregnancy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1997-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20958450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human endometrial decidual cell-associated 11 beta-hydroxysteroid dehydrogenase expression: its potential role in implantation.","authors":"F Arcuri,&nbsp;S Battistini,&nbsp;V Hausknecht,&nbsp;M Cintorino,&nbsp;C J Lockwood,&nbsp;F Schatz","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>During pregnancy excess corticosteroid exposure can disturb the normal pattern of growth and differentiation of the primate fetus. This is normally prevented by the action of 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD), which converts cortisol to its biologically inactive 11-oxo form, thereby ensuring that little or no cortisol is transferred to the fetus. During implantation, extravillous trophoblasts breech uterine vessels that are embedded in a decidual cell matrix. Through this invasive process the embryo gains requisite access to the maternal blood supply, while risking exposure to high circulating glucocorticoid levels. Thus, the expression of 11 beta-HSD by the decidual cell layer may be essential in regulating cortisol exposure of the developing embryo prior to placentation. In order to investigate the potential contribution of decidual cells to glucocorticoid metabolism, we evaluated the expression of both known 11 beta-HSD isoforms, 11 beta-HSD1, whose catalytic activity is NADP(+)-dependent, and NAD(+)-dependent 11 beta-HSD2, during decidualization of monolayers of human endometrial stromal cells. The differential actions of ovarian steroids on human endometrium are simulated in this in vitro model. Thus, progestins induce the expression of several decidualization markers in the cultured stromal cells, and consistent with its priming action in vivo, estradiol augments this expression. The results of our studies established a link between in vitro decidualization and enhanced glucocorticoid metabolizing capacity. Accordingly, the catalytic activities of both 11 beta-HSD isoforms were enhanced by incubation of the precursor stromal cells with medroxyprogesterone acetate, and further enhanced by estradiol, despite a lack of response to estradiol alone. This differential response to estradiol and progestin was reflected in parallel changes in steady state levels of 11 beta-HSD1 messenger RNA. The role of glucocorticoid metabolizing activity of the decidual cell is discussed in terms of its implications in determining the exposure of the implanting embryo to biologically active glucocorticoids.</p>","PeriodicalId":11444,"journal":{"name":"Early pregnancy : biology and medicine : the official journal of the Society for the Investigation of Early Pregnancy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1997-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20958600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The long-term effects of pregnancy and bromocriptine treatment on prolactinomas--the value of radiologic studies.","authors":"S Z Badawy,&nbsp;J C Marziale,&nbsp;A E Rosenbaum,&nbsp;J K Chang,&nbsp;S E Joy","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the long-term effects of pregnancy and bromocriptine treatment on prolactin-secreting pituitary tumors in women undergoing infertility treatment for prolactinomas.</p><p><strong>Methods: </strong>The records of 17 patients with prolactinomas were reviewed. Data regarding age, prepregnancy baseline and postpartum serum prolactin levels, and radiologic studies including CT or MRI were assessed. 16 patients were treated with bromocriptine before achieving pregnancy. Bromocriptine therapy was resumed after delivery for the duration of 1 to 14 years.</p><p><strong>Results: </strong>45% of pregnancies did not affect the size of prolactinomas, 27% of pregnancies showed a decrease in size of prolactinomas or radiologic evidence of resolution of the tumor and 27% of pregnancies demonstrated radiologic increase in the size of prolactinomas.</p><p><strong>Conclusions: </strong>It is safe for patients with prolactinomas to achieve pregnancy following bromocriptine treatment. Pregnancy may lead to a slight decrease in the size of prolactinomas, increase in size, no change, and in some cases, complete resolution. There were no visual field changes during the pregnancies. Pregnancy and long-term bromocriptine treatment may be helpful in reduction of the size of the tumor.</p>","PeriodicalId":11444,"journal":{"name":"Early pregnancy : biology and medicine : the official journal of the Society for the Investigation of Early Pregnancy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1997-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20958449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fetal rat brains contain luteinizing hormone/human chorionic gonadotropin receptors.","authors":"A A al-Hader,&nbsp;Y X Tao,&nbsp;Z M Lei,&nbsp;C V Rao","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The reverse transcription-polymerase chain reaction/Southern, Northern and Western blottings demonstrated that 19-day-old fetal rat brains contained the luteinizing hormone (LH)/human chorionic gonadotropin (hCG) receptor transcripts and receptor protein. Further investigation with Western blotting demonstrated that diencephalon, mesencephalon, rhombencephalon and telencephalon and several areas in each of these regions contained the LH/hCG receptor protein. The receptor protein levels in different regions were somewhat variable but they were not different from each other or from the whole brain. The 15-day-old fetal rat brains contained lower receptor protein levels which increased by 3-fold in 17-day-old and by 12-fold in 19-day-old fetal rat brains with no further significant increase in 21-day-old fetal, neonatal or adult rat brains. In summary, fetal rat brains contained LH/hCG receptors and these receptors were developmentally regulated. These findings suggest that the gonadotropins LH and hCG may regulate growth, development and differentiation in fetal brain.</p>","PeriodicalId":11444,"journal":{"name":"Early pregnancy : biology and medicine : the official journal of the Society for the Investigation of Early Pregnancy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1997-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20958451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can luteal phase serum estradiol concentrations predict karyotypes of spontaneous abortions?","authors":"A S Kaider,&nbsp;C Goodman,&nbsp;C B Coulam","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Low serum estradiol concentrations during pregnancy have been associated with spontaneous abortions. A large proportion of abortuses have chromosomal abnormalities. To determine whether serum estradiol during the luteal phase of conception cycles can predict the karyotype of spontaneous abortions, serum estradiol samples were drawn 11 days after embryo transfer from 52 women who subsequently had spontaneous abortions and chromosomal analysis was performed on the products of conception. The frequency of estradiol levels < 100 pg/ml was compared between normal and abnormal karyotypic spontaneous abortions. Chromosomal analyses among 52 spontaneous abortions revealed 14 (27%) to be normal and 38 (73%) abnormal. Among the 38 karyotypic abnormalities 30 were aneuploidy and eight were polyploidy. Serum estradiol levels were < 100 pg/ml in eight women (15%) and > 100 pg/ml in 44 women (85%). The frequencies of estradiol < 100 pg/ml in spontaneous abortions with normal (7%) and abnormal (18%) karyotypes were not significantly different. Thus, serum estradiol cannot predict the karyotype of spontaneous abortions.</p>","PeriodicalId":11444,"journal":{"name":"Early pregnancy : biology and medicine : the official journal of the Society for the Investigation of Early Pregnancy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1997-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20958452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnancy detection by ultrasound and chorionic gonadotropin during the peri-implantation period in the macaque (Macaca fascicularis).","authors":"A F Tarantal,&nbsp;L S Laughlin,&nbsp;J Dieter,&nbsp;J Tieu,&nbsp;A G Hendrickx,&nbsp;J W Overstreet,&nbsp;B L Lasley","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The goal of these studies was to correlate sonographic evidence of pregnancy during the peri-implantation period with the timing of the rise in monkey chorionic gonadotropin (mCG) as measured with an enzyme-linked immunosorbent assay. Animals were time-mated at mid-cycle, and ultrasound examinations were performed on postovulation days 12-15 (n = 77). Pregnancy was sonographically identified in 48 of 77 animals (62.3%), of which 28 had correlative ultrasound/endocrine data collected. For these animals, blood samples were obtained on postovulation days 12-15 for mCG assay. Pregnancy was identified by ultrasound on postovulation days 12 (6/28; 21.4%), 13 (6/28; 21.4%), 14 (8/28; 28.6%) or 15 (8/28; 28.6%). Seven of the 28 (25.0%) were found to have mCG levels consistent with pregnancy (> or = 1 ng/ml) on the same day as ultrasound confirmation, 12 of 28 (42.9%) were sonographically detected as pregnant 1 (n = 6), 2 (n = 3) or 3 (n = 3) days earlier than by mCG, and nine of 28 (32.1%) were found to have elevated mCG levels 1 (n = 7), 2 (n = 1) or 3 (n = 1) days earlier than ultrasound confirmation of pregnancy. The results of these studies have demonstrated (1) the utility of anatomical and endocrine techniques for detecting pregnancy approximately 3 days after the onset of implantation, and (2) the variation in the timing of implantation and the rise in circulating mCG in individual animals.</p>","PeriodicalId":11444,"journal":{"name":"Early pregnancy : biology and medicine : the official journal of the Society for the Investigation of Early Pregnancy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1997-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20958603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights into the mechanisms of vertical transmission of HIV-1. BIOMED2 Working Group on the in utero transmission of HIV-1.","authors":"E Menu,&nbsp;B Mognetti,&nbsp;M Moussa,&nbsp;V Nardese,&nbsp;L Tresoldi,&nbsp;C Tscherning,&nbsp;F X Mbopi Keou,&nbsp;S Dubanchet,&nbsp;P Mauclere,&nbsp;E M Fenyö,&nbsp;G Scarlatti,&nbsp;F Barre-Sinoussi,&nbsp;G Chaouat","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This paper is a summary of three oral presentations, as well as the ensuing discussion, at the Rijeka/Opatija 3rd Alps Adria Immunology meeting by three members of the European Biomed group on vertical transmission of HIV (G. Chaouat, F. Barre-Sinoussi, G. Scarlatti). This group also involves the laboratories of D. Dormont (CEA, Fontenay aux roses, France), P. Gounon (Electron Microscopy, the Pasteur Institute, France; Irène Athanassakis, University of Crete, Greece; Eva Maria Fenyö, Karolinska Institute, Sweden; and Larry Guilbert, Canada). As such, this paper intends to be neither a review, nor an original article, but rather is an opinion paper discussing the working hypothesis of this network, as well as some of their recent results, which were presented at this meeting. The paper was issued at the request of the organizers of the meeting.</p>","PeriodicalId":11444,"journal":{"name":"Early pregnancy : biology and medicine : the official journal of the Society for the Investigation of Early Pregnancy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1997-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20958599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Less miscarriage in pregnancy following Tamoxifen treatment of infertile patients with luteal phase dysfunction as compared to clomiphene treatment.","authors":"C H Wu","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>To compare the efficacy and the reproductive outcomes of Tamoxifen (TMX) vs. clomiphene citrate (CC) treatment in infertile women with luteal phase dysfunction.</p><p><strong>Methods: </strong>Eighty-seven consecutive infertile women with luteal phase dysfunction were randomly assigned to two treatment groups as: group 1 (TMX followed by CC) and group 2 (CC followed by TMX). The medications administered in the initial and the subsequent cross-over phase were given for 4 to 6 cycles except in those patients who achieved pregnancy within the first three cycles of treatment. The rates of pregnancy, spontaneous abortion and live-birth were calculated for comparison. Demographic profile and the frequency of other infertility factors between the two groups were comparable.</p><p><strong>Results: </strong>The pregnancy rates were similar between TMX and CC treatment (initial treatment phase: TMX, 50.0% vs. CC, 56.4%; subsequent treatment phase: CC, 33.3% vs. TMX, 47.1%), but the abortion rates were significantly lower (p < 0.05) in TMX treatments (initial treatment phase: 8.3% and subsequent treatment phase: 12.5%) than that of CC treatments (initial treatment phase: 22.7% and subsequent treatment phase: 62.5%). When the rates were calculated by pooling the patients according to the medication they received, the miscarriage rate was significantly lower (p < 0.05) if the patients conceived during the TMX treatment (9.4% vs. CC, 33.3%).</p><p><strong>Conclusions: </strong>Tamoxifen and clomiphene citrate seem to be similarly effective in achieving pregnancy in patients with luteal phase dysfunction. However, Tamoxifen therapy is associated with a lower incidence of spontaneous abortion; thus Tamoxifen may be the better choice for the therapy of infertile women with luteal phase dysfunction.</p>","PeriodicalId":11444,"journal":{"name":"Early pregnancy : biology and medicine : the official journal of the Society for the Investigation of Early Pregnancy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1997-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20958605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}